Showing results (121-130 of 259) with videos related to

Sort By:
Pageof 26
Blood|January 25, 2008
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemiaAllen W Ho, Evdoxia Hatjiharissi, Bryan T Ciccarelli, et al.
Blood|November 5, 2008
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemiaXavier Leleu, Lian Xu, Xiaoying Jia, et al.
Blood Advances|November 8, 2019
Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cellsTomasz Sewastianik, Maria Luisa Guerrera, Keith Adler, et al.
American Journal of Hematology|March 15, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström MacroglobulinemiaJorge J Castillo, Andrew R Branagan, Alberto Guijosa, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disordersDaniel Ditzel Santos, Evdoxia Hatjiharissi, Olivier Tournilhac, et al.
Clinical Lymphoma|March 30, 2005
Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemiaSophia Adamia, Steven P Treon, Tony Reiman, et al.
Blood|January 17, 2013
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionLian Xu, Zachary R Hunter, Guang Yang, et al.
Blood|March 3, 2018
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanismJiaji G Chen, Xia Liu, Manit Munshi, et al.
Biologics : Targets & Therapy|August 27, 2009
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasiasAldo M Roccaro, Irene M Ghobrial, Simona Blotta, et al.
British Journal of Haematology|November 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinibJorge J Castillo, Jithma P Abeykoon, Joshua N Gustine, et al.
Pageof 26